Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | President & COO, Lab Ops | March 01, 2022 | March 04, 2022 |
| SOPHiA GENETICS SASOPH · Entity 5228 | Chief Financial Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 244,157 |
Ending reported balance
After 2022-03-02 transaction · row 3
2 source rows · reconciled sequenceRow 2 · 2022-03-01 · Tax withholding · Disposed 503 · Balance 244,996 F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock. Row 3 · 2022-03-02 · Tax withholding · Disposed 839 · Balance 244,157 F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock. |
| Common StockSEC Table I · non-derivative | IndirectTrust by Self | 20,000 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 50,000 F3: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 192,500 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 192,500 F4: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 51,459 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 51,459 F5: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 48,768 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 48,768 F6: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 35,171 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 35,171 F7: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.95 · Expires 2028-07-05 | Direct | 40,502 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 40,502 F8: On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock.
F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.
F3: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F4: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F5: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F6: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F7: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F8: On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date.
SOPHiA GENETICS SA
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 306,726 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 1,592 · Balance 306,726 F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 1,592 | $8.10 | $12,897.43 |
DisclosureSEC source: 0001840706-26-000332 · wk-form4_1791403457.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,726 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 774 | $8.33 | $6,447.42 |
DisclosureSEC source: 0001840706-26-000318 · wk-form4_1790107327.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,318 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 1,592 | $5.29 | $8,419.45 |
DisclosureSEC source: 0001840706-26-000253 · wk-form4_1783454641.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,092 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 774 | $5.38 | $4,163.73 |
DisclosureSEC source: 0001840706-26-000228 · wk-form4_1782244876.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,684 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | PurchaseOrdinary Shares | 20,000 | $4.95 | $99,000.00 |
DisclosureSEC source: 0001840706-26-000205 · wk-form4_1780689734.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,458 F1 · shares: This purchase was made during an open trading window in accordance with the company's insider trading policy. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:02 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 1,403 | $4.85 | $6,800.62 |
DisclosureSEC source: 0001840706-26-000136 · wk-form4_1775851324.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,458 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.79 to $4.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,413 | $4.88 | $11,768.44 |
DisclosureSEC source: 0001840706-26-000123 · wk-form4_1775678666.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,861 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.70 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:04 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 2,520 | $4.85 | $12,210.91 |
DisclosureSEC source: 0001840706-26-000123 · wk-form4_1775678666.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,274 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.66 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:59 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 164,671 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000086 · wk-form4_1775213940.xml · derivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,671 Underlying: Ordinary Shares · 164,671 shares Expires 2036-04-02 F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 10:59 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 112,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000086 · wk-form4_1775213940.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,936 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 164,671 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001840706-26-000108 · wk-form4a_1775652436.xml · derivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,671 Underlying: Ordinary Shares · 164,671 shares Expires 2036-04-02 F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. Read SEC document |
| April 02, 2026 Filed Apr 8, 2026 12:47 UTC Amendment | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 112,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001840706-26-000108 · wk-form4a_1775652436.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,794 F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 297,794 ordinary shares. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:00 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | SaleOrdinary Shares | 774 | $4.79 | $3,704.52 |
DisclosureSEC source: 0001840706-26-000064 · wk-form4_1774036850.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,858 F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.72 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 00:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 839 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000041 · wf-form4_164635544947414.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President & COO, Lab Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,157 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 503 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000041 · wf-form4_164635544947414.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President & COO, Lab Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,996 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 61,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000277 · wf-form4_164090546675301.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President & COO, Lab Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,499 F1 · kind: On December 30, 2021, Mr. Cardoza was granted 61,143 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| July 05, 2021 Filed Jul 7, 2021 23:02 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 40,502 | $43.95 Strike: $43.95 | $1,780,062.90 |
DisclosureSEC source: 0001077183-21-000187 · wf-form4_162569890401981.xml · derivative · entry 8 CARDOZA GEORGE · CIK 0001518734 · President & COO, Lab Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,502 Underlying: Common Stock · 40,502 shares Expires 2028-07-05 F6 · derivative.exercise_date: On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| July 05, 2021 Filed Jul 7, 2021 23:02 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 7,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000187 · wf-form4_162569890401981.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President & COO, Lab Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,356 Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:56 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 31,107 | $40.11 | $1,247,701.77 |
DisclosureSEC source: 0001077183-21-000155 · wf-form4_162285098363912.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,772 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:56 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 169,230 | $40.39 | $6,835,199.70 |
DisclosureSEC source: 0001077183-21-000155 · wf-form4_162285098363912.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,879 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 35,171 | $53.17 Strike: $53.17 | $1,870,042.07 |
DisclosureSEC source: 0001077183-21-000080 · wf-form4_161482057286973.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,171 Underlying: Common Stock · 35,171 shares Expires 2028-03-02 F5 · derivative.exercise_date: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000080 · wf-form4_161482057286973.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,109 Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 77,074 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 77,074 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 77,074 | $45.48 | $3,505,325.52 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · nonDerivative · entry 5 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,902 Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 77,074 | $7.52 | $579,596.48 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · nonDerivative · entry 4 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,926 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · derivative · entry 6 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,074 Underlying: Common Stock · 72,926 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 52,926 | $45.19 | $2,391,725.94 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,902 Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 72,926 | $7.52 | $548,403.52 |
DisclosureSEC source: 0001077183-20-000215 · wf-form4_160634543123462.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-20-000180 · wf-form4_159709796772215.xml · derivative · entry 4 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 82,500 | $39.35 | $3,246,375.00 |
DisclosureSEC source: 0001077183-20-000180 · wf-form4_159709796772215.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,902 Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 100,000 | $7.15 | $715,000.00 |
DisclosureSEC source: 0001077183-20-000180 · wf-form4_159709796772215.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 48,768 | $28.33 Strike: $28.33 | $1,381,597.44 |
DisclosureSEC source: 0001077183-20-000037 · wf-form4_158328436965681.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,768 Underlying: Common Stock · 48,768 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 7,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000037 · wf-form4_158328436965681.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,402 Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,444 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 44,444 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Cardoza was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 19,444 | $23.15 | $450,128.60 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,831 Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 44,444 | $7.15 | $317,774.60 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 21:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 4,000 | $22.80 | $91,200.00 |
DisclosureSEC source: 0001077183-19-000188 · wf-form4_157324961050581.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,831 Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,556 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000188 · wf-form4_157324961050581.xml · derivative · entry 4 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,444 Underlying: Common Stock · 55,556 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Cardoza was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 51,556 | $22.82 | $1,176,507.92 |
DisclosureSEC source: 0001077183-19-000188 · wf-form4_157324961050581.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,831 Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 55,556 | $7.15 | $397,225.40 |
DisclosureSEC source: 0001077183-19-000188 · wf-form4_157324961050581.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 151,676 | $22.82 | $3,461,246.32 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · nonDerivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,831 Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · derivative · entry 4 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015 Mr. Cardoza was granted an option to purchase 200,000 shares. These options vest ratably over the first three anniversary dates of the grant. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 200,000 | $4.78 | $956,000.00 |
DisclosureSEC source: 0001077183-19-000057 · wf-form4_155717822198878.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 51,459 | $19.60 Strike: $19.60 | $1,008,596.40 |
DisclosureSEC source: 0001077183-19-000031 · wf-form4_155182329877820.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,459 Underlying: Common Stock · 51,459 shares Expires 2024-03-01 F1 · derivative.exercise_date: On March 1, 2019 Mr. Cardoza was granted an option to purchase 51,459 shares. These options vest ratably over the first four anniversary dates of the grant. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 8,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000031 · wf-form4_155182329877820.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,507 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $3.45 Strike: $3.45 | $103,500.00 |
DisclosureSEC source: 0001077183-19-000016 · wf-form4_155140091066370.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On March 5, 2014 Mr. Cardoza was granted an option to purchase 30,000 shares. These options vest ratably over the first three anniversary dates of the grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 30,000 | $3.45 | $103,500.00 |
DisclosureSEC source: 0001077183-19-000016 · wf-form4_155140091066370.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total includes 16,667 shares of unvested restricted stock that were previously reported in Table II. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock · Derivative | 8,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000030 · wf-form4_152763457965512.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting. F2 · derivative.exercise_date: Restricted stock will vest as follows; 8,333 shares vested on May 25, 2018, 8,333 shares will vest on May 25, 2019 and 8,334 shares will vest on May 25, 2020. F3 · derivative.expiration_date: These restricted shares will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000030 · wf-form4_152763457965512.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:47 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 192,500 | $8.03 Strike: $8.03 | $1,545,775.00 |
DisclosureSEC source: 0001209191-18-014677 · doc4.xml · derivative · entry 8 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2023-02-26 F8 · derivative.exercise_date: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.